Calderón Parra, JorgeGuisado Vasco, PabloMontejano Sánchez, RocíoEstrada Pérez, VicenteCuevas Tascón, GuillermoAguareles Gorines, JoséArribas, JoséErro Iribarren, MartaCalvo Salvador, MarinaFernández Cruz, AnaRamos Martínez, AntonioMuñez Rubio, Elena2023-06-222023-06-2220232077-038310.3390/jcm12030864https://hdl.handle.net/20.500.14352/72323This work was supported by the Research Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA), funding number 0040200108 (2.400€).Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/jcm12030864https://www.mdpi.com/journal/jcmopen access616.98:578.834578.834:616.98612.017COVID-19Monoclonal antibodiesSotrovimabSevere COVID-19Immunocompromised hostsEnfermedades infecciosas3205.05 Enfermedades Infecciosas